N-苄基-3-氨基苯磺酰胺 | 303780-52-1

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苄基-3-氨基苯磺酰胺
• 英文名称: 3-amino-N-benzylbenzenesulfonamide
• 英文别名: N-benzyl-3-aminobenzenesulfonamide
• CAS: 303780-52-1
• 化学式: C₁₃H₁₄N₂O₂S
• 分子量: 262.332
• InChiKey: BUBJRDZLVJJKLT-UHFFFAOYSA-N

物化性质

• 熔点：
  58-62°C
• 沸点：
  484.1±55.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090
• 储存条件：
  请保持冷静。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Benzyl 3-Aminobenzenesulfonamide
Synonyms: 3-Amino-N-benzylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Benzyl 3-Aminobenzenesulfonamide
CAS number: 303780-52-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H14N2O2S
Molecular weight: 262.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-苄基-3-氨基苯磺酰胺 在 盐酸 、 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 1-[3-(Benzylsulfamoyl)phenyl]-3-(4-carbamimidoylphenyl)urea
  参考文献：
  名称：

  磺酰基-苯基-脲基苯甲s; 新型的有效抗疟药结构类别。

  摘要：

  使用4SCan技术通过高效率的计算机筛选，将虚拟文库筛选到恶性疟原虫乳酸脱氢酶（LDH）的结构中，得到了一系列联苯脲化合物。这些经过化学优化，形成了新的有效抗疟药结构类别。该化合物不能充分抑制疟原虫LDH，不能充分说明其效力。因此，我们得出结论，未知的作用方式可能是抗疟疾活动的原因。

  DOI：

  10.1016/j.bmcl.2004.01.083
• 作为产物：
  描述：

  3-硝基苯磺酰氯 在 钯 TEA 、 氢气 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 N-苄基-3-氨基苯磺酰胺
  参考文献：
  名称：

  磺酰基-苯基-脲基苯甲s; 新型的有效抗疟药结构类别。

  摘要：

  使用4SCan技术通过高效率的计算机筛选，将虚拟文库筛选到恶性疟原虫乳酸脱氢酶（LDH）的结构中，得到了一系列联苯脲化合物。这些经过化学优化，形成了新的有效抗疟药结构类别。该化合物不能充分抑制疟原虫LDH，不能充分说明其效力。因此，我们得出结论，未知的作用方式可能是抗疟疾活动的原因。

  DOI：

  10.1016/j.bmcl.2004.01.083

文献信息

• Synthesis of new phenolic compounds and biological evaluation as antiproliferative agents
  作者：Marwa A Ibrahim、Riham F George、Sahar M Abou-Seri、Samir M El-Moghazy

  DOI：10.1177/1747519819895238

  日期：2020.3

  New series of phenolic azomethine compounds in addition to 5-arylidene thiazolidinones are synthesized and screened for their anticancer activity against the brain cancer cell line SNB-75 and non-small lung cancer cells HOP-92. The azomethine derivative 12b is the most active compound against SNB-75 displaying an IC50 value of 0.14 μM. Compounds 7b, 16a and 27d display submicromolar activity against

  合成了除 5-亚芳基噻唑烷酮外的新系列酚类偶氮甲碱化合物，并筛选了它们对脑癌细胞系 SNB-75 和非小肺癌细胞 HOP-92 的抗癌活性。偶氮甲碱衍生物 12b 是对 SNB-75 最具活性的化合物，IC50 值为 0.14 μM。化合物 7b、16a 和 27d 对 HOP-92 细胞系显示亚微摩尔活性，IC50 值分别为 0.73、0.74 和 0.81 μM。此外，研究最活跃的化合物对正常肺细胞 WI-38 的细胞毒性作用表明，化合物 7b、16a 和 27d 作为抗癌剂显示出高安全性。
• [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123738A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

  该发明涉及公式（I）中R1、R2、R3、R4、R5和p的化合物，其中这些参数在说明和权利要求中有定义，以及其药学上可接受的盐本身和作为药用活性物质，其制备方法，基于与该发明相符合的化合物的药物，以及它们的生产，以及在控制或预防上述疾病方面使用与该发明相符合的化合物，以及分别用于生产相应的药物。
• Synthesis and Anticandidal Activity of Azole-Containing Sulfonamides
  作者：Amjad M. Qandil、Mohammad A. Hassan、Nizar A. Al-Shar'i

  DOI：10.1002/ardp.200700125

  日期：2008.2

  aromatic ring. Secondary sulfonamides, 5l, 5m, and 5n showed activities that were proportional to their lipophilicity. The activities of N‐aryl‐substituted derivatives 5j, 5k, 5l, 5m, 5n, and 6j were also proportional to their lipophilicity. Halogenation enhanced the activity as a result of improvement of lipophilicity. The presence of two imidazole or triazole rings in the same compound did not show

  已经合成了 25 种含有一个咪唑或三唑环，或两个咪唑或三唑环的苯磺酰胺，并作为抗念珠菌剂进行了评估。活性最强的化合物为 5c、6b、6c、6e 和 17b，根据临床分离株的不同，MIC 值为 4.55-24.39 mM。将咪唑与三唑衍生物进行比较并没有显示出对活性的明显影响。考虑到含有 N-苄基的化合物具有额外的芳环，它们也没有显示出明确的活性证据。二级磺胺类药物 5l、5m 和 5n 显示出与其亲脂性成正比的活性。N-芳基取代衍生物5j、5k、5l、5m、5n和6j的活性也与其亲脂性成正比。作为亲脂性改善的结果，卤化增强了活性。
• Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure
  作者：Tomohiro Okawa、Yoshio Aramaki、Mitsuo Yamamoto、Toshitake Kobayashi、Shoji Fukumoto、Yukio Toyoda、Tsutomu Henta、Akito Hata、Shota Ikeda、Manami Kaneko、Isaac D. Hoffman、Bi-Ching Sang、Hua Zou、Tetsuji Kawamoto

  DOI：10.1021/acs.jmedchem.7b00443

  日期：2017.8.24

  for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2

  用于心力衰竭的一类新型治疗药物，高效和选择性的GRK2抑制剂，在体外研究中表现出增强的β-肾上腺素信号传导能力。HTS将衍生物5和1,2,4-三唑衍生物24a鉴定为命中化合物。新一代的脚手架和所有部分的SAR研究都产生了带有N-苄基羧酰胺部分的4-甲基-1,2,4-三唑衍生物，对GRK2的活性很高，对其他激酶的选择性更高。在亚型选择性方面，这些化合物对GRK1、5、6和7表现出足够的选择性，并且对GRK3具有几乎相同的抑制作用。我们的药物化学努力导致发现了115h（GRK2 IC 50= 18 nM），获得了与人GRK2和GRK2抑制剂的共晶体结构，该抑制剂增强了β-肾上腺素能受体（βAR）介导的cAMP积累，并防止了用异丙肾上腺素处理过的表达β2AR的HEK293细胞中βAR的内在化。因此，115h似乎是心力衰竭治疗的一种新型疗法。
• [EN] ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE<br/>[FR] COMPOSÉS D'ISOQUINOLÉINE, LEURS MÉTHODES DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES DANS DES MALADIES ASSOCIÉES À L'ALTÉRATION DE L'ACTIVITÉ DE LA BÊTA GALACTOSIDASE
  申请人：MINORYX THERAPEUTICS S L

  公开号：WO2018122746A1

  公开（公告）日：2018-07-05

  The application is directed to compounds of formula (I) : (I), and formula (IA): (IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta- 1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B.

  该申请涉及以下式(I)：(I)和式(IA)：(IA)及其盐和溶剂合物，其中R1、R2、R3、R4、R5、n、A1、A2、A3和Y如规范中所述，以及它们的制备方法，包括相同的药物组合物，以及用于治疗和/或预防与β-半乳糖苷酶活性改变相关的疾病的用途，特别是β-半乳糖苷酶或GLB 1的活性改变，包括GM 1 神经节苷脂病和莫基奥综合症B型。